Title
Variable clinical features in patients with Fabry disease

Permalink
https://escholarship.org/uc/item/55d1q9c6

Journal
Molecular Genetics and Metabolism, 120(1-2)

ISSN
1096-7192

Authors
Tapia, Daisy
Hall, Kathy
Alandy-Dy, Jousef
et al.

Publication Date
2017

DOI
10.1016/j.ymgme.2016.11.340

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Variable clinical features in patients with Fabry disease

Daisy Tapia, Kathy Hall, Joulef Alandy-Dy, Margaret Knight, Dawn Lombardo, Madeleine Pahl, Virginia Kimonis, University of California Irvine, Irvine, CA, United States

We report our experience with Fabry disease in a multidisciplinary clinic in UC Irvine. Our cohort comprises two children and 17 adult patients (10 M and 9 F) ranging in age from 6- 62 y., with age of diagnosis ranging from 3-57. The data shows that 42% of all patients suffer gastrointestinal problems, 53% have reduced sweating, 63% have angiookeratomas, 58% exhibit corneal whorls, 32% have lymphedema, and 90% of the male patients experienced acropaesthesia. 53% of adults have tinnitus, 41% of adults experience hearing loss. There is renal involvement in 37% of patients, most have varying levels of proteinuria but one required a kidney transplant. Thirty-two percent of patients have evidence of cardiomyopathy determined by echocardiogram and MRI studies. One male had a stroke and currently has MRI changes of multifocal encephalomalacia and adjacent gliosis of the left cerebral hemisphere, frontal and parietal lobes. Ninety percent of the males, 44% of the females, and 50% of the children currently receive enzyme replacement therapy (ERT). Each individual demonstrates different response rates to symptom improvement and slowing of organ deterioration. Two individuals developed infusion reactions, one male developed ERT associated meningitis in 2009 which prompted him to end treatment. He re-initiated ERT May 2015 and has continued to tolerate ERT with premedication. ERT will be initiated in the 6 year old male for reduced GFR, a urine GL-3 level of 569μg/mmol Cr. Clinical features are phenotypically heterogeneous, perhaps due to the variety of unique mutations in the GLA gene. Monitoring patients regularly provides insight into genotype- phenotype correlations thus leading to optimization of patient care.